Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1 (+) CD8 (+) T cells in HCC via blocking VEGFR2

Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1(+) CD8(+) T cells in HCC microenvironment have not been systematically studied. Here, we established an orth...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Zhibin, Gao, Xingxing, Pan, Caixu, Wu, Qinchuan, Wang, Shuai, Qian, Junjie, Xu, Zhentian, Xu, Kangdi, Zhou, Lin, Zhen, Shushen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067412/
https://www.ncbi.nlm.nih.gov/pubmed/36609997
http://dx.doi.org/10.1111/cas.15719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067412/
https://www.ncbi.nlm.nih.gov/pubmed/36609997
http://dx.doi.org/10.1111/cas.15719

Ejemplares similares